LGX818 is an investigational drug that blocks the activity of an abnormal form of a protein called BRAF, which promotes the growth of melanoma. This study is assessing LGX818 plus a second drug in patients whose melanoma has continued to grow while on LGX818 therapy alone. Patients will receive LGX818 with one of the following investigational anticancer drugs: MEK162, BGJ398, BKM120, INC280, or LEE011.
These other drugs work in the following ways:
- MEK162 inhibits a protein called MEK1/2, which drives cancer growth.
- BGJ398 works by inhibiting an enzyme involved in cancer growth called FGFR kinase.
- BKM120 blocks a molecule called PI3 kinase, which appears to function abnormally in many cancers.
- INC280 is designed to inhibit cancer growth by blocking the activity of an enzyme cancer cells need called “c-MET receptor tyrosine kinase.”
- LEE011 blocks a protein called CDK, which tells melanoma cells to divide.
All of the drugs being assessed in this study are taken orally (by mouth).